ANL 22.45 Decreased By ▼ -0.65 (-2.81%)
ASC 15.96 Decreased By ▼ -0.14 (-0.87%)
ASL 22.40 Increased By ▲ 0.15 (0.67%)
BOP 8.40 Decreased By ▼ -0.15 (-1.75%)
BYCO 8.80 Decreased By ▼ -0.16 (-1.79%)
FCCL 17.91 Decreased By ▼ -0.16 (-0.89%)
FFBL 24.95 Increased By ▲ 0.50 (2.04%)
FFL 17.32 Decreased By ▼ -0.58 (-3.24%)
FNEL 8.23 Decreased By ▼ -0.17 (-2.02%)
GGGL 21.43 Decreased By ▼ -0.66 (-2.99%)
GGL 41.20 Decreased By ▼ -1.98 (-4.59%)
HUMNL 7.05 Increased By ▲ 0.03 (0.43%)
JSCL 20.35 Decreased By ▼ -0.50 (-2.4%)
KAPCO 37.96 Increased By ▲ 0.06 (0.16%)
KEL 3.55 Decreased By ▼ -0.06 (-1.66%)
MDTL 2.99 Decreased By ▼ -0.01 (-0.33%)
MLCF 36.67 Increased By ▲ 0.37 (1.02%)
NETSOL 151.40 Decreased By ▼ -1.90 (-1.24%)
PACE 5.85 Decreased By ▼ -0.13 (-2.17%)
PAEL 31.10 Decreased By ▼ -0.10 (-0.32%)
PIBTL 9.31 Decreased By ▼ -0.05 (-0.53%)
POWER 7.91 Increased By ▲ 0.01 (0.13%)
PRL 20.25 Decreased By ▼ -0.60 (-2.88%)
PTC 10.34 Decreased By ▼ -0.06 (-0.58%)
SILK 1.71 Increased By ▲ 0.04 (2.4%)
SNGP 44.67 Increased By ▲ 1.48 (3.43%)
TELE 22.20 Increased By ▲ 0.14 (0.63%)
TRG 174.60 Increased By ▲ 1.10 (0.63%)
UNITY 35.60 Decreased By ▼ -0.60 (-1.66%)
WTL 3.18 Decreased By ▼ -0.07 (-2.15%)
BR100 4,961 Decreased By ▼ -18.06 (-0.36%)
BR30 24,423 Decreased By ▼ -37.02 (-0.15%)
KSE100 46,528 Decreased By ▼ -107.87 (-0.23%)
KSE30 18,422 Decreased By ▼ -58.36 (-0.32%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
27,246
4024hr
Pakistan Cases
1,226,008
2,16724hr
4.22% positivity
Sindh
450,787
Punjab
422,790
Balochistan
32,769
Islamabad
104,242
KPK
171,388
Pakistan

Pakistani pharma in negotiation with Gilead to manufacture COVID-19 drug

BFBL was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesi
12 May 2020
  • BFBL was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesivir to supply in Pakistan and 126 other countries.

Pakistan pharmaceutical company Ferzsons Laboratories informed that its subsidiary BF Biosciences Ltd (BFBL) was in negotiations with Gilead Sciences Inc for the manufacture and sale of Remdesivir.

In its filing to the Pakistan Stock Exchange (PSX), Ferozsons informed that its listed subsidiary BF Biosciences Limited (BFBL) was negotiating for a non-exclusive license agreement with Gilead Sciences Inc to manufacture and sell Remdesivir to supply in Pakistan and 126 other countries. “There is no obligation at this time for any party to execute any transaction,” Ferozsons told the PSX.

“If an agreement is executed by Gilead and BFBL, once production starts, we are confident that we will have sufficient quantities over time to serve the needs of the patients in Pakistan,” the company added.

“However, at the moment we are uncertain as to the timelines for first launch as an agreement remains to be executed, and thereafter local regulatory approvals and sourcing of Active Pharmaceutical Ingredient for manufacturing Remdesivir may take some time.”

It may be mentioned here that Remdesivir has been approved by the US FDA for the treatment of COVID-19 treatment. “The optimal duration of treatment was under ongoing clinical trials. Under the EUA, both 5-day and 10-day treatment durations have been suggested based on the severity of the disease.”

 

 

 

Comments

Comments are closed.